ReviewClinical & translational immunology2014
Vaccines to prevent leishmaniasis.
Review in Clinical & translational immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 161 citations in OpenAlex.
- Recent advances in Phlebotomine sand fly research: a review based on studies presented at ISOPS XI.Parasite (Paris, France) · 2025Review
- The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024Article
- Non-Vesicular Lipid Transport Machinery inInternational journal of molecular sciences · 2023Review
- Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination.Frontiers in immunology · 2023Review
- Validating Immunomodulatory Responses of r-Pathogens (Basel, Switzerland) · 2022Article
- Review
- Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis.International journal of peptide research and therapeutics · 2022Article
- Review
- TheGenes · 2021Article
- Interleukin-4 Responsive Dendritic Cells Are Dispensable to Host Resistance AgainstFrontiers in immunology · 2021Article
- Designing of a Novel Fusion Protein Vaccine Candidate Against Human Visceral Leishmaniasis (VL) Using Immunoinformatics and Structural Approaches.International journal of peptide research and therapeutics · 2021Article
- Unraveling the Role of Immune Checkpoints in Leishmaniasis.Frontiers in immunology · 2021Review
- Xenodiagnosis to address key questions in visceral leishmaniasis control and elimination.PLoS neglected tropical diseases · 2020Review
- The potential impact of human visceral leishmaniasis vaccines on population incidence.PLoS neglected tropical diseases · 2020Article
- Intralesional Injection of Mouse Mesenchymal Stem Cells Reduces IL-10 Production and Parasite Burden inCell journal · 2020Article
- Iron and Heme Metabolism at the Leishmania-Host Interface.Trends in parasitology · 2020Review
- Differential immune response modulation in early Leishmania amazonensis infection of BALB/c and C57BL/6 macrophages based on transcriptome profiles.Scientific reports · 2019Article
- Protective or Detrimental? Understanding the Role of Host Immunity in Leishmaniasis.Microorganisms · 2019Review
- Article
- Leishmanicidal effects of amphotericin B in combination with selenium loaded on niosome againstJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniasis is a parasitic disease that encompasses a range of clinical manifestations affecting people in tropical and subtropical regions of the world. Epidemiological and experimental data indicate that protection from disease can be achieved in most people. In addition, we know how the host immune system must respond to infection in order to control parasite growth. However, there is still no vaccine for use in humans. Here, we review our understanding of host immunity following Leishmania infection and also discuss recent advances in the development of vaccines to prevent leishmaniasis, highlighting a new promising approach that targets the parasite hemoglobin receptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.